SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-013187
Filing Date
2017-11-14
Accepted
2017-11-14 16:03:55
Documents
78
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 916592
2 ex31-1.htm EX-31.1 20033
3 ex31-2.htm EX-31.2 19570
4 ex32-1.htm EX-32.1 10160
  Complete submission text file 0001493152-17-013187.txt   4877139

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE immy-20170930.xml EX-101.INS 798736
6 XBRL SCHEMA FILE immy-20170930.xsd EX-101.SCH 65193
7 XBRL CALCULATION FILE immy-20170930_cal.xml EX-101.CAL 92745
8 XBRL DEFINITION FILE immy-20170930_def.xml EX-101.DEF 217560
9 XBRL LABEL FILE immy-20170930_lab.xml EX-101.LAB 448369
10 XBRL PRESENTATION FILE immy-20170930_pre.xml EX-101.PRE 336683
Mailing Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130
Business Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130 858-704-4042
Imprimis Pharmaceuticals, Inc. (Filer) CIK: 0001360214 (see all company filings)

IRS No.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35814 | Film No.: 171201396
SIC: 2834 Pharmaceutical Preparations